Product Description
An oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine.
Mechanisms of Action: TOP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Germany | India | Pakistan | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Zhejiang University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Acute Myeloid Leukemia
Phase 1: IgA Nephropathy|Diarrhea|Dementia, Vascular|Vascular Cancer|Neutropenia|Hereditary Autoinflammatory Diseases|Eye Cancer|Brain Cancer|Stroke|Vision, Low|Immune Complex Diseases|Conduct Disorder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ChiCTR2400088404 | N/A |
Not yet recruiting |
Acute Myeloid Leukemia |
2029-02-28 |
|
| WangHH | N/A |
Recruiting |
Acute Myeloid Leukemia |
2024-01-21 |
|
| hhhWang | P3 |
Recruiting |
Acute Myeloid Leukemia |
2024-01-21 |
|
| RVCL | P1 |
Completed |
Immune Complex Diseases|Diarrhea|Eye Cancer|Brain Cancer|Vascular Cancer|IgA Nephropathy|Neutropenia|Conduct Disorder|Dementia, Vascular|Stroke|Hereditary Autoinflammatory Diseases|Vision, Low |
2020-07-23 |